Search - tctmd.com

Displaying 21 - 40 of 210

Sort: Relevancy | Date

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

Caitlin E. Cox

May 24, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

L.A. McKeown

May 19, 2021

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

Presentation TCT 2020

TCT 286: Long-Term Outcomes Following Drug-Eluting Balloon Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis: Multicenter Propensity Score-Matched Analysis (DEB-Dragon Registry)

Presenter: Wojciech Wanha

October 14, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

March 27, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News CRT 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Michael O'Riordan

February 25, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Advertisement

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

TCT 286: Long-Term Outcomes Following Drug-Eluting Balloon Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis: Multicenter Propensity Score-Matched Analysis (DEB-Dragon Registry)

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content